Contec Bio: Quadrivalent Influenza Virus Split Vaccine Receives Drug Registration Certificate

Kangtai Biological announces that the four-valent influenza virus split vaccine developed by the company has received the “Drug Registration Certificate” issued by the National Medical Products Administration today.
The four-valent influenza virus split vaccine is suitable for people aged 3 and above, capable of stimulating the body’s immune response against influenza viruses, and is used to prevent influenza caused by vaccine-related strains of the influenza virus.

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin